ORIC
Oric Pharmaceuticals, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 24 ▼ 1 insider sell $702.7K at $13.51
- Jul 6 ▼ 1 insider sell $3.6K at $12.00
- Jul 24 ▼ 1 insider sell $157.5K at $12.02
- Aug 26 ▼ 1 insider sell $1.1M at $13.69
- Sep 23 BTIG initiates
- Sep 24 to Oct 1 ▼ 3 days of insider sells: $275.9K by 2 insiders, avg $13.33
- Oct 5 FDA: ORIC® Pharmaceuticals Announces Agreement with Cancer Rese…
- Oct 5 Leerink Partners initiates
- Oct 5 ▲ ORIC Pharmaceuticals announced a partnership with Cancer Research UK…
- Oct 20 ▼ 1 insider sell $189.4K at $13.53
- Oct 23 ▲ ORIC Pharmaceuticals presented updated Phase 1b data for enozertinib…
- Oct 30 ▲ Short interest falls 30.4% to 10.73M
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $2.4M.
- InstitutionsBULLISH
Q3 2026: 23 added (0 new), 11 trimmed or exited.
- AnalystsBULLISH
20 of 22 rate it Buy or better. Every target is above the price.
- Short sellersCOVERING
Short interest −30.4% to 10.73M shares. 4.8 days to cover, ≈10.3% of shares.
- TrendDOWNTREND
34% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Qube Research & Technologies Ltd | DOUBLED | $22.1M |
| Candriam S.C.A. | TRIM | $10.7M |
| ROYCE & ASSOCIATES LP | TRIM | $7.2M |
| HRT FINANCIAL LP | DOUBLED | $6.9M |
| Nuveen, LLC | DOUBLED | $6.5M |
| CITIGROUP INC | TRIM | $2.5M |
| Jump Financial, LLC | ADD | $2.5M |
| Russell Investments Group, Ltd. | ADD | $2.0M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
22 analystsPrice is below the lowest target. Median implies +213%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 28, 2026 | BTIG REITERATE | Buy |
| Oct 27, 2026 | Wedbush MAINTAIN | Outperform |
| Oct 26, 2026 | Stifel MAINTAIN | Buy |
| Oct 14, 2026 | JP Morgan MAINTAIN | Overweight |
| Oct 5, 2026 | Leerink Partners INITIATE | Outperform |
| Sep 23, 2026 | BTIG INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Piscitelli Dominic Chief Financial Officer Oct 20, 2026 | EXERCISE | $61.0K |
Piscitelli Dominic Chief Financial Officer Oct 20, 2026 | SELL | $189.4K |
Heyman Richard A. Director Oct 1, 2026 | SELL | $41.3K |
Heyman Richard A. Director Oct 1, 2026 | EXERCISE | $5.6K |
Heyman Richard A. Director Oct 1, 2026 | SELL | $45.2K |
Piscitelli Dominic Chief Financial Officer Sep 28, 2026 | EXERCISE | $58.4K |
Piscitelli Dominic Chief Financial Officer Sep 28, 2026 | SELL | $181.3K |
Piscitelli Dominic Chief Financial Officer Sep 24, 2026 | EXERCISE | $2.6K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
10 filings · 2 press releases · 1 bullish · 0 bearish · 2 mixed · 7 neutral- NEUTRAL PRESS-RELEASENov 16, 2026
ORIC reported a Q3 2026 net loss of $48.1M ($0.44 per share), wider than the $32.6M loss a year ago, as R&D spending jumped 51% to $43.4M to support late-stage trials. The company initiated the Himalayas-1 global Phase 3 trial for rinzimetostat in mCRPC and announced plans for a Redwood-1 Phase 3…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
EcoR1 Capital, LLC filed an amended Schedule 13G disclosing a 2.9% passive stake in Oric Pharmaceuticals as of September 30, 2026, down from a prior filing. The filing confirms the stake remains well below the 5% threshold, indicating a reduction in position.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
T. Rowe Price Associates filed an amended Schedule 13G disclosing a 4.9% passive stake in Oric Pharmaceuticals as of September 30, 2026, down from a prior filing. The filing confirms the stake remains below the 5% threshold, indicating a reduction in position.
🔒 Fresh report (last 24h), subscribers only
- MIXED INST-CLUSTERNov 9, 2026
Institutional activity in ORIC during Q3 2026 was mixed: 7 small buyers added $2.1M net, while 4…
The divergence between large sellers (trimming or exiting) and small buyers (adding modestly) suggests institutional conviction is weakening. Monitor upcoming earnings and any pipeline updates for…
All ORIC filing & press-release reports (12)
- PRESS-RELEASE reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- INST-CLUSTER reportNov 9, 2026
- 8-K reportOct 23, 2026
- PRESS-RELEASE reportOct 5, 2026
- CLUSTER reportOct 2, 2026
- PRESS-RELEASE reportAug 3, 2026
- 8-K reportJun 22, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 4, 2026
- PRESS-RELEASE reportApr 3, 2026